AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03962660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HaRTS-TRENDS
Description: HaRTS-TRENDS comprises 4, individual sessions delivered in the context of the interventionist's pragmatic harm-reduction mindset paired with a compassionate, advocacy-oriented heart-set or style. It comprises the delivery of 4 manualized components, including a) participant-led tracking of preferred smoking outcomes, b) elicitation of participants' harm-reduction goals and their progress toward achieving them, c) discussion of the relative risks of various nicotine delivery systems, and d) instruction in using ENDS. Additionally, HaRTS-TRENDS entails provision of commercially available ENDS.
Study NCT03962660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (SC)
Description: The 4-session, individual standard care control condition entails the well-documented and evidence-based 5 As intervention (i.e., Ask about nicotine use, Assess use, Advise to quit smoking, Assist with exploring current smoking/planning smoking cessation, Arrange follow-up). Part of arranging follow-up is the recommendation to call the smoking quit line, which can supply additional counseling and nicotine replacement therapy.
Study NCT03701555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP003
Description: PvP003 tablet orally.
Study NCT01325701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: ibrutinib is an inhibitor of BTK
Study NCT03405701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVM
Description: Patients in IVM group will receive FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and the ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
Study NCT03405701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: Patients in IVF arm will undergo controlled ovarian hyperstimulation with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
Study NCT02618707 — intervention group
Intervention type: OTHER
Intervention: Lactate
Description: Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
Study NCT02582359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: Dose of 1.5 mg or 2.3 mg or 3.0 mg taken by mouth on days 2, 5, 9, 12 of each cycle.
Study NCT02582359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction: cytarabine 100 mg/m2/day continuous infusion, days 1-7 Consolidation: cytarabine 2000 mg/m2/day, 3 hour infusion, on days 1-5
Study NCT02582359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Daunorubicin 60 mg/m2, IV bolus, on days 1-3 of induction, only.
Study NCT03906786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: The intervention will consist of 4 structured medical consultations in the form of a motivational interviewing compared to usual care, covering a 12-month intervention period. In both groups, the frequency of visits (c / 3 months) and the variables collected will be the same.
Study NCT04604496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 20MG
Description: PF-06882961 in 20 mg oral tablet will be administered on Day 1
Study NCT02691312 — intervention group
Intervention type: DEVICE
Intervention: Digital Retinography System
Description: The DRS is a portable non-mydriatic fundus camera in which children place their chin on a chin rest and the camera, after auto-focusing, takes photographs of their retinas. These photographs will be examined by an ophthalmologist (specializing in retinal disease) to assess for evidence of diabetic retinopathy.
Study NCT02513693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard neuromuscular blockade
Description: Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
Study NCT02513693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Description: Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
Study NCT03701555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP003 150 mg
Description: PvP003 150 mg
Study NCT00795600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Insulin detemir once daily plus insulin aspart at mealtime
Study NCT00795600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Insulin NPH once daily plus insulin aspart at mealtime
Study NCT01286779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX 326 (Recombinant factor IX)
Description: The treatment with BAX 326 will be at the discretion of the investigator and will consist of either twice weekly prophylactic treatment with 50 IU/kg, modified prophylaxis, or on-demand treatment.
Study NCT00344682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: memantine 5mg - 20mg PO daily
Study NCT00344682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg - 20mg PO daily over 8 weeks
Study NCT03320447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine-prilocaine 5% cream application
Description: The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
Study NCT03320447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2940-nm Er:YAG AFL pretreatment
Description: After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
Study NCT03320447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyl-aminolevulinate application
Description: Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
Study NCT03320447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Illuminating using red light-emitting diode lamps
Description: Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
Study NCT01952912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PkEP
Study NCT01952912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OP
Study NCT01197040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 1 mg/kg/day for 4 weeks. Then, the dose will be progressively tapered if the remission will be achieved. For patients who exhibit incomplete remission at this time, high dose steroid will be continued for 4 weeks again before the tapering.
Study NCT01197040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acid mycophenolic (Myfortic)
Description: patients will receive prednisone 0.5 mg/kg/day combined with mycophenolic acid (MyforticR) 1440 mg/day. The management of steroid therapy will be identical in both groups, while MyforticR will be continued for six months
Study NCT01925183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2a
Description: 180mcg once weekly; subcutaneous injection
Study NCT01925183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 600mg two times daily (BID) (e.g. 3x200mg at 6am, 3x200mg at 6pm) in patients ≥75kg body weight; 2x200mg at 6am and 3x200mg at 6pm in patients \<75kg; orally
Study NCT01925183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: 800mg three times daily (TID) (e.g. 4x200mg at 6am, 4x200mg at 2pm, 4x200mg at 10pm); orally
Study NCT02897544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Manualized Health Education Intervention
Study NCT02167633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression surgery
Description: Patients will undergo posterior decompression/laminectomy on relevant spinal levels depending on neurological symptoms. If there is a need of spinal stabilization after decompression, patients will undergo posterior instrumentation with pedicle screws and titanium rods. Instrumentation will be done two or three levels above and below each level with metastatic affection.
Study NCT02167633 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in 1 fraction to cover as large a fraction as possible the defined target volume
Study NCT02167633 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fractionated Radiotherapy
Description: Patients allocated to surgery will receive postoperative radiotherapy commencing between 10 to 21 days after decompressive surgery. Target should include the entire vertebral body and the vertebral arch at the operated level of the vertebral column.~Patients receiving postoperative radiotherapy will receive 30 Gy in 10 fractions with 3 Gy pr. fraction. The prescribed dose should cover at least 90 % of the defined target volume.
Study NCT02167633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: All patients referred with clinical suspicion of metastatic spinal cord compression will receive high dose glucocorticoids. Dose adjusted to risc of side effects.
Study NCT02167633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: All patients referred with clinical suspicion of metastatic spinal cord compression will receive high dose glucocorticoids. Dose adjusted to risc of side effects.
Study NCT02167633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: All patients receiving high dose glucocorticoids will also be prescribed with pantoprazole 40/daily to prevent gastric ulcers
Study NCT02167633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: All patients receiving high dose glucocorticoids will also be prescribed with pantoprazole 40/daily to prevent gastric ulcers
Study NCT01381172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimizer System
Description: The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
Study NCT01381172 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention: Optimal medical therapy
Description: The control group receives optimal medical therapy only.
Study NCT02620553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin
Description: There is a study drug dose increase once during the study. The dose increase will occur 6 months after entering into the study. A total of 6 children will be included at each dose (3 children will not have received insulin prior to entering the study and 3 children will have received a lower dose of insulin for 6 months). Further dose increases or more frequent dose increases in individual children will not be performed during Pre-POINT. Escalation will occur in both treatment and placebo group so that participants and study investigators will remain blinded to treatment throughout the study. First dose (2.5 mg oral insulin/day) Second dose (7.5 mg oral insulin/day) Third dose (22.5 mg oral insulin/day) Fourth dose (67.5 mg oral insulin/day)
Study NCT02491307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginger.io Smartphone Application
Description: Daily use of the Ginger.io smartphone application
Study NCT02440074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mesenchymal stem cells
Description: Bone marrow collection from patient, mesenchymal cells isolation and expansion under Good Manufacturing Practice (GMP) conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by intradiscal injection.
Study NCT02350322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schoolmeal with fatty fish
Description: Schoolmeal with fatty fish three times a week for 12 weeks
Study NCT02350322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schoolmeal without fish
Description: Schoolmeal with meat/cheese three times a week for 12 weeks
Study NCT02350322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Description: Omega-3 capsules three times a week for 12 weeks
Study NCT02620553 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Oral Placebo is given orally daily
Study NCT04376541 — intervention group
Intervention type: DRUG
Intervention: Fentanyl
Description: amount of fentanyl used in both groups
Study NCT04421144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthognathic surgery
Description: patients with maxillofacial disharmony will undergo orthognathic surgery using CAD/CAM Cutting Guides and Customized Titanium Plates.
Study NCT00418392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple aspiration with minocycline pleurodesis
Description: Intrapleural instillation of 300mg minocycline within 5 min after simple aspiration
Study NCT00418392 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: simple aspiration
Description: Simple aspiration for primary spontaneous pneumothorax by pigtail catheter
Study NCT02105506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tachosil patch
Study NCT02362880 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Florbetaben
Description: single dose of Florbetaben followed by PET scan
Study NCT02362880 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Florbetaben
Description: single dose of Florbetaben followed by PET scan
Study NCT01858662 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metastases Resection ( multiple steep surgery possible)
Description: Metastases resection will be process by surgery, after a randomized chemotherapy (FOLFOX or FOLFIRI) + Target therapy (Cetuximab). The surgery will allow to compare the pathological response on the resected metastases by the chemotherapy + target therapy type.
Study NCT01858662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracile
Description: 5-FU bolus 400 mg/m2, IV bolus every 2 weeks 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion every 2 weeks
Study NCT01858662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin L
Description: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion
Study NCT01858662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, 2-hour IV infusion every 2 weeks
Study NCT01858662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, 1.30-hour IV infusion every 2 weeks
Study NCT01858662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 400 mg/m² in 100 ml NaCl 0.9% 2-hour IV infusion for 1rst cycle and after the 1rst cycle 250 mg/m² in 100 ml NaCl 0.9% 1-hour IV infusion
Study NCT00592995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creatine monohydrate
Description: 10 to 30 grams daily
Study NCT00592995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 to 30 grams daily
Study NCT03175653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxycodone Pill A
Description: Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
Study NCT03175653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Pill B
Description: Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
Study NCT01086657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-AVIDNA036-00-VP
Description: H5 DNA Vaccine
Study NCT01086657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine
Description: Inactive H5N1 Vaccine
Study NCT03356912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel drug products should be administered only by intravenous route.~Prednison should be administered by oral route
Study NCT03356912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: Cabazitaxel drug products should be administered only by intravenous route.~Prednison should be administered by oral route
Study NCT03356912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone should be administred by oral route
Study NCT02491320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-treatment acupuncture
Description: Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks.
Study NCT02491320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Starting from 2.5mg daily from day 3-5 for 5 days after a spontaneous period or after a withdrawal bleeding following progestin, one time per day.Participants are treated for up to 4 cycles.
Study NCT02491320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Starting from 2.5mg daily from day 3-5 for 5 days after a spontaneous period or after a withdrawal bleeding following progestin, one time per day.Participants are treated for up to 4 cycles.
Study NCT01243333 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F-18]fluorodeoxyglucose
Description: Undergo PET scans with \[F-18\]fluorodeoxyglucose
Study NCT01243333 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F-18]fluorothymidine
Description: Undergo PET scans with fluorine \[F-18\]fluorothymidine
Study NCT01243333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scans with 3 radiotracers (fludeoxyglucose F 18, fluorine F 18 fluorothymidine, and water O-15)
Study NCT01243333 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Water O-15
Description: Undergo PET scans with water O-15 tracers
Study NCT02811562 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: manikin
Study NCT02811562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manikin
Study NCT02811562 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fiberoptic bronchoscope
Study NCT02811562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fiberoptic bronchoscope
Study NCT02811562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pentax-airwayscope
Study NCT01247974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorMatrix ECM for Pericardial Closure
Description: Circumferential closure of the pericardium following CABG surgery using the CorMatrix ECM for Pericardial Closure
Study NCT04359420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BC-Predict
Description: BC-Predict is an automated system for offering an assessment of breast cancer risk to women when they receive their NHS Breast Screening Programme invitation, and generating letters to feedback this risk to women and relevant healthcare professionals. Women at higher risk are offered chemoprevention drugs and additional mammography
Study NCT04359420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NHS Breast Screening Programme
Description: usual care from NHS Breast Screening Programme, consisting of mammography every three years for most women.
Study NCT02594137 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Without watertight duraplasty
Description: After standard craniectomy and dural opening, provided there is no brain contusions or hematomas requiring surgical evacuation, no watertight duraplasty is performed. The dura is left opened and the brain parenchyma is covered with Surgicel. Usual closure is then performed.